Novartis's Sandoz licenses proposed multiple sclerosis biosimilar

Swiss drugmaker Novartis's Sandoz division has licensed from Polpharma Biologics a proposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord.

from Reuters: Health News https://ift.tt/2Ln61Vd
via IFTTT